Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

The oral multi-targeted tyrosine kinase inhibitor (TKI) anlotinib is effective for non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, a fraction of patients remains non-responsive, raising the need of how to identify anlotinib-responsive patients. In the present study, we ai...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Oncol
Main Authors: Lu, Jun, Shi, Qin, Zhang, Lele, Wu, Jun, Lou, Yuqing, Qian, Jie, Zhang, Bo, Wang, Shuyuan, Wang, Huimin, Zhao, Xiaodong, Han, Baohui
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Oncology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6749025/
https://ncbi.nlm.nih.gov/pubmed/31572680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00886
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki